New Hampshire will receive nearly $30 million as part of a $7.4 billion national settlement with Purdue Pharma and the Sackler family, Attorney General John Formella announced Tuesday. The settlement closes one of the most-watched chapters of the litigation that followed the OxyContin-driven wave of opioid addiction, and the state’s share will be channeled into drug treatment and recovery — a sector that, in New Hampshire, has spent the better part of a decade operating with too little capacity for the demand it faces.
The announcement, which Formella made public through the state Department of Justice and was reported by NHPR, represents the resolution of years of multistate negotiations following Purdue’s bankruptcy and the long fight over whether the Sackler family — Purdue’s owners — could shield personal assets from civil claims by routing them through the company’s reorganization. After a U.S. Supreme Court decision rejecting an earlier broader Sackler liability shield, the parties returned to the table, and the result is a settlement structure that pairs corporate dollars with billions in direct contributions from individual Sackler family members.
What the $30 Million Means for New Hampshire
Thirty million dollars is real money in a state with roughly 1.4 million residents, but it is also money against the backdrop of a crisis that has carved through New Hampshire harder than almost any state in the country. New Hampshire’s overdose death rate spiked early in the fentanyl wave and has remained stubbornly high. The state’s network of treatment programs — the regional “doorways” model, residential treatment beds, methadone clinics, sober living houses, peer-recovery services — has scaled meaningfully since 2017 but still cannot consistently meet demand in every part of the state.
Formella’s office signaled that the new dollars would flow into treatment and recovery rather than backfill general state spending or court costs. That distinction matters. Earlier opioid settlements have been criticized in some states for being absorbed into general funds. New Hampshire has thus far been more disciplined about ringfencing settlement money for direct services, in keeping with the recommendations from the state’s Opioid Abatement Trust Fund.
How the $30 million will be split between programs is a separate question that the trust fund’s advisory commission will work through over coming months. The recurring tension is between expanding capacity (more beds, more clinicians, more medication-assisted treatment slots) and sustaining the recovery infrastructure that helps people stay in remission once they leave acute treatment. Both are needed; neither is cheap.
Where Purdue and the Sacklers Stand Now
The $7.4 billion deal brings the Purdue and Sackler litigation closer to a final accounting. Under the settlement, the Sackler family has agreed to pay billions over time and step away from the pharmaceutical industry. Purdue itself will be reorganized into a public-benefit company whose profits will fund opioid abatement work rather than enrich shareholders. The terms remain subject to court approval and finalization, but the broad shape is what state attorneys general spent years pushing for after the original settlement structure collapsed at the Supreme Court.
For New Hampshire, the settlement is the latest installment in a long string of opioid-related recoveries from manufacturers, distributors, and pharmacies. Combined, those settlements have brought hundreds of millions of dollars into the state’s abatement infrastructure. The Purdue piece is symbolically significant because Purdue is widely viewed as the company whose marketing of OxyContin in the late 1990s and early 2000s helped ignite the crisis. Holding it accountable — and holding the family that owned it personally accountable — has been a core demand of the families and treatment advocates who have spent two decades carrying the loss.
The Treatment-Side Reality
New Hampshire’s recovery community has watched this case closely. The state has active concerns about how methadone clinics operate and an underlying healthcare system in which Medicaid is doing more work than its line-item suggests. Both will shape what the $30 million can accomplish. Settlement money that adds residential beds is helpful, but only if Medicaid reimbursement rates make those beds operationally viable. Settlement money that pays for peer recovery coaches helps, but only if those coaches can find sustainable employment and supervision.
The core lesson from a decade of opioid-response work in the state is that single-source dollars do not solve the problem; structural payment reform plus sustained funding plus workforce investment do. Thirty million dollars from Purdue does not fix New Hampshire’s substance use disorder system, but applied carefully, it can deepen what already works.
What to Watch Next
Final court approval of the settlement, the Opioid Abatement Trust Fund commission’s allocation decisions, and the legislature’s approach to the state’s broader behavioral health budget are the three near-term items worth tracking. New Hampshire will not be the only state asking how to make settlement money stretch into durable infrastructure rather than one-time grants. Other states’ early experiences — both successes and missteps — will shape how the commission writes its rules.
For families still living with the costs of the crisis, the announcement carries a different weight. Settlement dollars do not undo a death or a prison sentence or a foster placement. What they can do is fund the people who pick up the phone the next time someone is at the doorway asking for help.
For related coverage, see our reporting on New Hampshire To Receive $29.5 Million From Purdue Pharma And The Sackler Fam….
